✦ LIBER ✦

OC3.06.5 ROLE OF CIRCULATING TUMOUR MARKER CA19.9 AND ANTIANGIOGENIC THERAPY WITH BEVACIZUMAB IN PATIENTS WITH METASTATIC COLORECTAL CANCER ON FIRST LINE SYSTEMIC TREATMENT

✍ Scribed by G. Del Vecchio Blanco; V. Formica; I. Portarena; A. Caruso; E. Mannisi; M. Massara; I. Grenga; L. Rossi; F. Pallone; M. Roselli

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comment on ‘Capecitabine and bevacizumab

✍ Molina-Garrido, M J; Guillén-Ponce, C 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 104 KB

The use of high dose d,l-leucovorin in f

✍ Budai, B.; Nagy, T.; Láng, I.; Hitre, E. 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 325 KB

6004 ORAL Role of Baseline Circulating T

✍ Sastre, J.; Vidaurreta, M.; Gomez, A.; Rivera, F.; Valladares-Ayerbes, M.; Calle 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB

A retrospective observational study on t

✍ López, R; Salgado, M; Reboredo, M; Grande, C; Méndez, J C; Jorge, M; Romero, C; 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 320 KB

PCN69 COST-EFFECTIVENESS OF FIRST-LINE C

✍ M Gyldmark; R Aultman; U Siebert; E Sabate 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

A Phase III Randomized, Open-Label, Cont

✍ Zev Wainberg; J. Randolph Hecht 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 90 KB